Paindrainer AB and IHE publish US Health Economic Study highlighting excessive cost to society and payers for chronic pain
MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, in collaboration with the Institute of Health Economics (IHE), has undertaken and unveiled considerable costs in a health economic study. The study underscores the substantial impact of chronic pain on the cost to both society, health organisations and payers. In addition, it also sheds light on the potential for improvement through the utilization of a digital self-management tool like Paindrainer®.
The main outcomes of the study are:
- Chronic pain is associated with a significant burden, including a low quality-of-life, significant healthcare costs and production loss, thus highlighting the unmet need to society as a whole.
- Based on data from a multicenter clinical trial, the total mean societal gain per patient and year was estimated to around $8,700, consisting of a monetized health gain ($4,550 per patient and year), production gain ($3,370 per patient and year), and healthcare cost savings ($797 per patient and year).
- The study points out that a digital tool for self-management of chronic pain, such as Paindrainer®, may improve all these components.
“We are extremely pleased that the study reaffirms what we have known for some time: chronic pain is an enormous burden to society as a whole. Most certainly for the affected individuals in terms of significant lower quality of life, but also for the society in terms of huge healthcare costs and great production losses. We are confident that our AI-powered self-management tool Paindrainer® can fulfill this unmet need and bring about substantial improvements.”, says Erik Frick CEO Paindrainer AB.
The study is published on https://en.ihe.se/publicering/the-societal-cost-savings-and-health-related-quality-of-life-gains-associated-with-a-digital-tool-for-self-management-of-chronic-pain-paindrainer-a-feasibility-study/
“The utility of patients who obtained improved pain experience and its monetized value, is estimated very conservative, to $4,550. This utility value is based on the valuation of a full health year of $50,000. This is in the low range ($50,000 to $200,000) of what the Institute for clinical and Economic Review (ICER) in the US recommends in their value assessment framework, Sept 25, 2023. Still there is a significant economic impact to payers and society as a whole.”, says Prof. Ulf Persson, Senior Advisor IHE.
For more information, please contact:
Erik Frick
CEO Paindrainer AB
erik.frick@paindrainer.com
+46 736 612123
Sara Olofsson
Research Director, IHE
Sara.olofsson@ihe.se
+46 730 796415
About Paindrainer AB
Paindrainer AB is a company developing digital platforms and applications contributing to health and well-being. Paindrainer was founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors. The idea was born when Maria, after participating in several pain rehabilitation programs, realized that the pain is affected by many more factors than the human brain can comprehend.
Paindrainer® is the first evidence-based AI powered digital tool demonstrating improved quality of life in patients suffering from chronic pain.
Paindrainer® coaches the users in managing their pain and planning their day not to exceed a certain pain level, and to ensure that there is enough energy left for highly valued activities. The solution is powered by leveraging advanced algorithms and is fully adaptive to each patient, a feature called 360o patient-centricity©.
Paindrainer® (Paindrainer PD1) is an FDA registered Medical Device Class 1 (510k exemption), MDR compliant and CE certified.